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Summary Primitive neuroectodermal tumours (PNET's) or medulloblastomas are common primary brain
tumours of childhood. Current treatment protocols achieve 50-60% cures. However, it has proved difficult to
develop better treatment for the remaining patients because prognostic factors are not established. We have
investigated the prognostic value of p53 protein expression in 87 PNET's using immunohistochemistry with
DO-7 and CM-1 antibodies on biopsy paraffin sections. Eight patients (9%) had intensely reactive tumour cell
nuclei, and a significantly reduced survival (P = 0.002); only one survives and this with a recurrent tumour 50
months following diagnosis. Sixty eight per cent of patients had faintly reactive tumour cell nuclei, a reduced
survival up to 4 years but a long term survival not significantly different (P = 0.41) from 23% of patients with
p53 negative PNET's; the 10 year survival rates were 37% and 40%, respectively. Males had a reduced
survival (P = 0.04) with a 2-fold relative risk of death compared to females. Multivariate analysis showed that
intense overexpression of p53 protein identifies a group of PNET patients with a 7-fold relative risk of death
compared to all other cases, irrespective of sex. This marked difference suggests the involvement of p53 in the
pathogenesis of PNET's which have a particularly poor response to treatment, and should help to develop new
therapies for this group of patients.
Primitive neuroectodermal tumours (PNET's) represent
between 20 to 25% of all primary brain tumours of child-
hood. They develop most frequently in the cerebellum when
they are usually known as medulloblastomas. Although fatal
if untreated, current treatment regimens achieve 50-60% 5-
year survival rates for medulloblastomas (Tait et al., 1990).
At the present time neither clinical nor histopathological
features in medulloblastomas reliably identify which tumours
will recur (Caputy et al., 1987), making it difficult to develop
new therapeutic strategies. A recent Newcastle study has
shown that mitotic index and overexpression of the c-erbB2
protooncogene have some prognostic value in medulloblas-
tomas (Gilbertson et al., 1992), and this led to an examina-
tion of additional molecular biological features of PNET's
and their use as prognostic markers.
Derangements in- the tumour suppressor gene p53, which
maps to chromosome l7pl3.1 (Solomon & Barker, 1989)
may be involved in the pathogenesis of PNET's since 11 of
34 informative cases show loss of constitutional heterozy-
gosity for polymorphic markers on chromosome 17pl1.2-pter
(James et al., 1990; Raffel et al., 1990). Mutations in the p53
gene led to accumulation of p53 protein to 10-100-fold
above normal values (Reich et al., 1983; Iggo et al., 1990). At
these concentrations immunohistochemically detectable p53
have been shown to be associated with malignant progression
and poor prognosis in a variety of human tumours, including
astrocytoma (Jaros et al., 1992). Although previous studies
have identified overexpression of p53 in some PNET's (Jaros
et al., 1992; Barbareschi et al., 1992; Loda et al., 1992), the
number of cases examined was too small to assess its prog-
nostic value. In this report we have used p53 antibodies
effective on paraffin sections (DO-7 and CM-1) to determine
prognostic significance of p53 expression in archival biopsy
material of 87 cases of PNET's with a known clinical out-
come.
Material and methods
Archival formalin-fixed-paraffin-embedded biopsy tissue from
87 PNET's were available from the Departments of
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Neuropathology, Newcastle General Hospital (79), and Mid-
dlesbrough General Hospital (8) between June, 1963 and
September, 1990. Of the patients who died only those known
to have died from tumour progression or a metastasis were
included in the study. The age of the patients ranged from
one month to 34 years, with 68 of the patients (78%) aged
from one month to 15 years. Thirty two of the patients were
female and 55 were male. The histopathology of all the
PNET's has been reviewed according to the WHO
classification system (Rorke et al., 1985). Eighty of the
PNET's (92%) came from the cerebellum and could therefore
be classified as medulloblastoma (Russell & Rubinstein, 1989;
Table I). Seven (8%) of the tumours came from extracerebel-
lar sites. None of these extracerebellar tumours fulfilled the
diagnostic criteria for cerebral neuroblastoma (Russell &
Rubinstein, 1989), they all had areas where tumour cells had
nuclear and cytoplasmic characteristics indistinguishable
from medulloblastomas (for further details see footnotea in
Table I). The majority of patients had been treated with
surgical resection plus cerebrospinal irradiation, a smaller
group had surgery combined with radio- and chemotherapy,
and only a small proportion of patients had been treated
with surgery alone (Table II).
Immunohistochemistry
The sections were incubated with mouse monoclonal
antibodies to human p53 protein (DO-7; Novocastra) at a
1:50 dilution, or with rabbit polyclonal antibodies to human
p53 protein (CM-1 from Novocastra) at a 1:500 dilution.
The antibody binding was visualised using the ABC kit
(Vectastain) followed by diaminobenzidine at 0.5 mgmlh-'
and a haematoxylin counterstain, as described previously
(Jaros et al., 1992). Sections from a glioblastoma multiforme,
overexpressing p53 protein, were used as positive controls for
both the DO-7 and the CM-1 antibodies. Negative control
sections were achieved by omitting the primary antibodies.
Whole sections from each PNET were examined at x 400
magnification and, where appropriate, the proportion of
tumour cell nuclei with detectable levels of p53 was cal-
culated using a squared graticule. The total number of nuclei
counted in each PNET ranged between 700 to 1000 cells. The
p53 labelling index (LI) was calculated as a percentage of p53
reactive, vs total number of tumour cell nuclei (LI =
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Table I Clinical characteristics, p53 labelling index, and mitotic index in the four p53 immunohistochemical reactive groups of primitive
neuroectodermal tumours
Tumour site
extra-cellebellarl Age: years p53 LI % MI %
p53 IHC Number of % of Femalel cerebellar Median Median Mean
Group intensity patients patients Male ratio ratioa (range; n)b (range; n) (s.d.; n)
A intense 8 9 3/5 2/6 3.5 (1/12-30;8) 30.2 (6.0-60.4;8) 3.08 (0.60;5)
vs group B SC vs group B NSd
vs group C Sc
vs group D Sf
B faint 21 24 7/14 2/19 9 (2-24;21) 4.7 (1.3-27.2;21) 2.23 (1.33;15)
C faint 38 44 13/25 1/37 8 (7/12-34;38) <0.1 2.02 (1.02:23)
D negative 20 23 9/11 2/18 5.5 (1 -25;20) 0.0 1.45 (0.85;12)
vs group B NS9
vs group C NSh
IHC= immunohistochemical; LI = labelling index; MI = mitotic index; S= statistically significant; NS = not statistically significant. aThe 7
extracerebellar PNET's came from the following sites: The first PNET (group A) was from the left occipital lobe and had histopathological
features indistinguishable from cerebellar medulloblastoma; it was negative for synaptophysin (Syn, marker for neuronal differentiation) but
had focal positivity for glial fibrillary acidic protein (GFAP, marker for astrocytic differentiation); this patient was alive at last assessment
though with recurrent tumour and spinal metastases. The second PNET (group A) was from the right fronto-parietal lobe and had areas
indistinguishable from medulloblastoma plus areas with multinucleated giant cells; it had focal positivity for both Syn and GFAP (died). The
third PNET (group B) was a cauda equina metastasis occurring 9 years after a diagnosis of cerebellar medulloblastoma with which it shared its
histopathological features and focal Syn and GFAP positivity (alive). The fourth PNET (group B) was from the left fronto-temporal lobe and
had features indistinguishable from cerebellar medulloblastoma with focal GFAP positivity but was negative for Syn (died). The fifth PNET
(group C) was from the third ventricle and right hypothalamus and had features indistinguishable from cerebellar medulloblastoma with focal
positivity for GFAP but was negative for Syn (alive with recurrent tumour). The sixth PNET (group D) was from the base of the spine (L4/5)
and had nuclear and cytoplasmic features of a PNET with focal Syn positivity; there was no evidence on histopathological or
immunohistochemical grounds of it being an ependymoma, chordoma, astrocytoma, teratoma or nerve sheath tumour (alive). The seventh
PNET (group C) was from the right fronto-parietal lobe; it had areas indistinguishable from cerebellar medulloblastoma plus areas with
oligodendroglial-like histology; it had focal GFAP positivity but was negative for Syn (alive). bp = 0.75, d.f. = 3; CP = 0.0007, 95% Confidence
Interval for differences in medians (12.4, 42.0); dp= 0.13, d.f. = 51; ep= 0.04, d.f. = 51; P = 0.006, d.f. = 51; gP= 0.065, d.f. = 51; hp= 0.14,
d.f. = 51.
Table II Types of treatment that PNET patients received within the four p53
immunohistochemical reactive groups
% of patients
% of patients % of patients who who had surgery
Total number who had surgery had surgery & & radiotherapy
Group of patients alone radiotherapy & chemotherapy
A 8 12.5 75.0 12.5
B 21 0.0 71.4 28.6
C 38 5.3 55.3 39.5
D 20 10.0 65.0 25.0
100 x number of reactive nuclei . total number of nuclei).
The PNET's were divided into four reactive groups (A, B, C,
and D) based on the intensity of the p53 immunohis-
tochemical reaction, and on the number of tumour nuclei
which were p53 positive (see Results for details).
Statistical analysis
Since the data for p53 LI and age were not normally dis-
tributed a Mann-Whitney test was used to analyse differences
in p53 LI (Siegel & Castelan, 1988). The median ages of the
reactive groups A, B, C and D were compared using the
Kruskal-Wallis test (Siegel & Castelan, 1988). Mitotic indices
(MI's) were available for 55 of the 87 PNET's from the
present series (Gilbertson et al., 1992). One-way Analysis of
Variance (ANOVA) was used to analyse differences between
the mean MI's of the four p53 labelling groups. Comparisons
between groups were made by using the pooled standard
deviation (s.d.) from the ANOVA and a Student's t-test.
Prognostic importance of the categorised variables, i.e. p53
immunohistochemical reactive intensity and sex, was assessed
using a Log-Rank test and Kaplan-Meier estimates (Peto et
al., 1977). Sex and the continuous variables, i.e. age and p53
LI were also separately entered into the Cox regression
model (Cox, 1972) to yield relative risks and P-values. The
multivariate analysis was performed by using a forward step-
wise application of Cox's Regression model via the BMDP
statistical package (Program 2).
Results
Immunohistochemistry ofp53
Similar staining patterns were obtained with both the DO-7
and CM-1 antibodies, except that the CM-1, unlike the DO-
7, antibody, produced a diffuse non-specific background reac-
tion. The non-specific reaction made the categorisation of
PNET's with the CM-1 antibody less clear-cut, and the
tumours with negative and faintly reactive tumour cell nuclei
were particularly difficult to identify. The following results
are, therefore, based on the superior DO-7 antibody. In 67
PNET's (77%) p53 protein was immunohistochemically
detectable in tumour cell nuclei, either as an intense or as a
faint reaction product. Based on the intensity of the p53
immunohistochemical reaction, as determined by two
independent observers (E.J. and R.H.P., who were found to
be in agreement), and the number of p53 positive tumour
nuclei, the tumours were divided into four reactive groups, A,
B, C and D (Table I): A 8 PNET's (9%) contained numerous
intensely reactive, and some faintly reactive tumour cell
nuclei (example of intense reactivity found in group A is
shown in Figure 1); B 21 PNET's (24%) had numerous
faintly reactive but none intensely reactive tumour cell nuclei
(example of faint reactivity found in group B is shown in
Figure 2); C 38 PNET's (44%) had few faintly, and none
intensely reactive nuclei; D 20 PNET's (23%) showed no
detectable nuclear labelling. Subsequently, percentages of p53
reactive tumour cell nuclei = p53 LI (see Material andp53 OVEREXPRESSION AND PROGNOSIS IN PNET 803
Figure 1 Example paraffin section of a PNET from group A
showing intense reactivity (dark brown) of tumour cell nuclei
with DO-7 antibody to p53 protein. Non-reactive tumour cell and
endothelial cell nuclei (e.c.) show only blue haematoxylin
counterstain. Scale bar = 30 pm.
Figure 2 Example paraffin section of a PNET from group B
showing faint reactivity (pale brown) of tumour cell nuclei with
DO-7 antibody to p53 protein.
methods) were calculated for gropps A and B (Table I). The
median p53 LI of group A was 30.2% (range from 6.0% to
66.4%) and significantly greater (P = 0.0007) than the
median p53 LI of group B which was 4.7% (range from
1.3% to 27.2%). In all PNET's from group C the p53 LI was
<0.1%. The p53 overexpression was generally restricted to
tumour cell nuclei, although in a few cases faint reaction was
also detectable in endothelial nuclei: in two PNET's from
group A, two PNET's from group B, and two PNET's from
group C. None of the tumours showed cytoplasmic p53
reactivity in either the tumour or the endothelial cells. No
staining was detected in normal cerebellar grey matter (21
cases) or in normal choroid plexi adjacent to tumours (five
cases).
Group A had the highest mean MI which was significantly
different from the mean MI's of group C (P = 0.04) and D
(P = 0.006) but not of group B (P = 0.13; Table I). There
was no significant difference between the mean MI's of
groups B, C, and D. All groups were similarly heterogeneous
with respect to sex, age, and site of tumour (Table I), and
treatment they received (Table II). The differences in median
ages between the four groups were not significant (Kruskal-
Wallis test P = 0.75).
Prognostic significance ofp53 reaction intensity, p53 labelling
index, sex, and age
Univariate Log-Rank test for categorised variables was used
to analyse the prognostic importance of p53 reaction inten-
sity and sex. PNET patients from groups B and C had
similar life tables (P = 0.63) allowing them to be pooled into
one 'faintly-reactive' group (59 cases), which represented
68% of all the patients. The eight patients in group A with
intensely reactive tumour cell nuclei had a significantly
reduced survival (P = 0.002) compared to the 'faintly-
reactive' (pooled group B and C) and negative cases (group
D); only one of these patients (13%) has survived 50 months
following diagnosis, and this patient is currently suffering
from a recurrent tumour (Figure 3). The patients with faintly
reactive nuclei (pooled B and C) had a reduced survival
during the first 4 years compared to the patients with
negative (D) PNET's (P = 0.037) but the long term survival
was similar in the two groups (P = 0.42); the 10 year survival
rates were 37% and 40% respectively, using the Kaplan-Meier
estimates. Of the seven tumour specimens derived from ext-
racerebellar sites five were alive at the last clinical assessment,
one of them from group A (Table I). The extracerebellar
PNET's therefore did not contribute to the increased mortality
observed in group A.
Males had a significantly reduced survival than females
(P = 0.04); the 10 year survival rates were 29% and 47%,
respectively, using Kaplan-Meier estimates (Figure 4). The
increased relative risk of death for males was taken into
account by adjusting the effect of p53 reaction intensity for sex
when performing multivariate analysis by forward stepwise
application of Cox's regression model. Multivariate analysis
showed that the 10 year survival of patients with 'faintly-
reactive' nuclei (pooled group B and C) was similar to patients
with negative tumours (group D, relative risk of death was
1.29, Table III, Model 1), indicating no significant difference
(P = 0.46) in relative risk of death for patients in groups B, C,
and D. Multivariate analysis comparing survival between
patients in the intensely reactive group (group A) and patients
in all the other groups (pooled group B, C, and D) revealed a
relative risk ofdeath for patients in group A of 6.71 (Table III,
Model 2, P = 0.0002). This analysis indicates that patients with
intensely reactive PNET's have a poor prognosis, irrespective
of their sex.
Univariate Cox's regression model was used to analyse the
prognostic importance of sex and continuous variables, i.e. age
and p53 LI (Table IV). Only sex was significant (P = 0.04),
while age and p53 LI were not (P = 0.11, P= 0.33, respec-
tively). Note also, that being male increases the relative risk of
death compared to being female by 1.9 times. Therefore, the
effect of age and p53 LI was adjusted for sex, when using
multivariate analysis by forward stepwise application of Cox's
regression model (Table V). Although the significance of both
variables increased to borderline statistical significance when
adjusted for sex P = 0.052, P = 0.072, respectively), the actual
adjusted effect was very small, as can be seen from virtually
identical relative risks for age and p53 LI in Tables IV and V.
Multivariate analysis of the prognostic importance of all the
variables examined in this and the previous study (Gilbertson
et al., 1992), together with the histopathological and
immunohistochemical features of the PNET's and the various
treatment regimens the patients received will be a subject of a
separate paper.
Discussion
This study has demonstrated that p53 immunohistochemistry
with DO-7 antibodies detects p53 protein overexpression in
tumour cell nuclei of PNET's at two levels, intense and faint,
but that only the intense overexpression identifies a group of
9% of patients with a particularly poor prognosis. High p53
labelling index, without regard for the p53 reaction intensity,
was not of prognostic importance. These observations suggest
that intense p53 overexpression is associated with greater
tumour growth potential and/or tumour promoting activity
than the faint p53 overexpression. The precise molecular
mechanisms underlying these differences is not known at pre-
sent, although experiments designed to elucidate the relation-
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Figure 3 Survival curves for PNET patients in relation to p53 reaction intensity of tumour cell nuclei: p53 negative (group D) -,





Figure 4 Survival curves for PNET patients in relation
P = 0.04; d.f. = 1.
Time (months)
to sex: females , n = 32; males -, n = 55. Log-Rank statistic = 4.24;
The wild type (wt) p53 protein is involved in negative
regulation of cell growth (Finlay et al., 1988). In normal
quiescent cells it has a short half-life of about 6-30 min, and
is present at low cellular levels, undetectable by immunohis-
tochemistry (Reich et al., 1983; Iggo et al., 1990). In many
different types of tumours, including lung, breast,
oesophageal, endometrial, and colorectal carcinomas high
levels of immunohistochemically detectable p53 protein
(10-100-fold above normal values) correlate with point
mutations or small in-frame deletions in four evolutionary
conserved domains of exons 5 to 8 (de Fromentel & Soussi,
1992). The mutants show either loss of tumour suppressor
function or gain of dominant transforming ability, but
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Table III Multivariate analysis by forward stepwise application of Cox's regression
model for sex and p53 immunohistochemical intensity
95% CI for
Variable Coefficient s.e. Relative risk relative risk P-value
Model I
Sex: 0.596 0.327 1.82 0.96-3.44 0.07
M vs F
p53 IHC intensity: 0.261 0.346 1.29 0.66-2.60 0.46
group B & C
vs group D
Model 2
Sex: 0.856 0.321 2.35 1.25-4.42 0.008
M vs F
p53 IHC intensity: 1.90 0.491 6.71 2.42-18.67 0.0002
group A vs
groups B & C & D
IHC = immunohistochemical; s.e. = standard error; CI = confidence interval.
Table IV Univariate analysis (Cox's regression) for sex, age and p53 labelling index
95% CI for
Variable Coefficient s.e. Relative risk relative risk P-value
Sex: M vs F 0.641 0.305 1.90 1.04-3.45 0.04
Age -0.028 0.018 0.97 0.94-1.01 0.11
p53 LI 0.010 0.011 1.01 0.98- 1.03 0.33
LI = labelling index; s.e. = standard error; CI = confidence interval.
Table V Multivariate analysis by forward stepwise application of Cox's regression model
for sex, age and p53 labelling index
95% CI for
Variable Coefficient s.e. Relative risk relative risk P-value
Sex: M vs F 0.699 0.302 2.01 1.11-3.64 0.022
Age -0.037 0.019 0.96 0.93- 1.00 0.052
p53 LI 0.021 0.012 1.02 0.99- 1.05 0.072
LI = labelling index; s.e. = standard error; CI = confidence interval; M = male;
F = female.
efficiencies (Hinds et al., 1990), and p53 mutations alone do
not appear to be able to transform cells. To effect full
transformation p53 mutants require the cooperation of
activated ras and/or myc oncogenes (Reihsaus et al., 1990).
Furthermore, though the cell lines immortalised by p53
mutations also show accumulation of p53 with moderately
increased half-lives (to about 1 h), only their transformation
with activated ras and/or myc oncogenes leads to vastly
elevated levels of mutant p53 with half-lives further extended
to 10 h (Gjerset et al., 1992). This suggests that in most
PNET patients with intense or high level of p53 overexpres-
sion and poor prognosis (group A), the DO-7 antibody has
detected mutant forms with mutations in exons 5 to 8, and
that the cooperation of activated oncogenes or other tumour
suppressor genes is likely to be involved, both in the level of
overexpression and in the transformation efficiency of p53.
Candidate genes for cooperation with p53 in PNET's have
yet to be identified. Amplification, rearrangement, or muta-
tion of c-myc (Raffel et al., 1990; Bigner et al., 1990; MacG-
regor & Ziff, 1990), overexpression of the c-erbB2 proto-
oncogene (Gilbertson et al., 1992) and/or non-random abnor-
malities of chromosomes 1, 6, or 16 reported to occur in
subgroups of PNET's (Griffin et al., 1988; Thomas & Raffel,
1991) suggest possible candidates and others will no doubt
follow as the genetic alterations in PNET's are further char-
acterised. Several observations indicate that non-mutational
mechanisms can also lead to high levels of p53 overexpres-
sion in cells, though because of their relative rarity they are
unlikely to be an explanation for the p53 overexpression in
the bulk of the PNET's. First, wt p53 may be overexpressed
due to an aberrant expression of cellular transcriptional
regulators of the p53 gene (Ronen et al., 1991). High level of
p53 mRNA expression has so far been detected in one
medulloblastoma cell line (Loda et al., 1992) and hence
requires further investigation. Second, complex formation
between wt p53 and viral oncogenes (Reich et al., 1983) is
unlikely to be responsible for the intense p53 overexpression,
since there is no evidence of a viral aetiology for PNET's. A
further alternative is aberrant post-translational processing of
wt p53, as recently reported as a germ-line defect in a family
with cancer predisposition (Barnes et al., 1992).
The faint or low level of p53 overexpression identified in
68% of PNET patients with an intermediate prognosis
(pooled groups B and C) may have several explanations. The
DO-7 antibody reacts with both the wt and the mutant forms
of human p53 protein (Vojtesek et al., 1992). It has a greatly
improved sensitivity compared to the Pab 1801 antibody
(Vojtesek et al., 1992) which we employed originally (Jaros et
al., 1992). The wt p53 can become elevated to about 3-4-fold
above levels found in quiescent cells, either in mitogen-
stimulated cells through regulation of p53 at the level of
transcription (Reich & Levine, 1984), or in response to treat-
ment with DNA damaging agents through post-translational
stabilisation mechanism (Kastan et al., 1991). It is possible
that in some PNET's from group B and C the DO-7
antibody has detected the wt p53 which became elevated
through the first of these two mechanisms. The faint reac-
tivity with the DO-7 antibody in the hyperplastic endothelial
nuclei of 7% of the PNET's supports this possibility. How-
ever, the DNA damaging agents are unlikely to be involved
in any of the PNET's since all the samples were obtained
prior to radio- or chemo-therapy. Alternatively, in groups B
and C the DO-7 antibody may have detected moderately
elevated levels of p53 mutants, similar to those that occur in
non-transformed but immortalised cell lines in the absence of
contributory effects from activated oncogenes (Gjerset et al.,806 E. JAROS et al.
1992). Lastly, the similar long-term survival rates of PNET
patients in the faintly reactive group and the negative group
suggests that in the negative group either abnormalities in
genes other than p53 are involved in their development or
that the p53 gene is affected by large deletions, splicing and
nonsense mutations, or missense mutations outside of exons
5 to 8, as all these abnormalities can lead to loss of p53
function in the absence of p53 expression (Bodner et al.,
1992).
This investigation has identified a group of PNET patients
whose particularly poor response to treatment is associated
with intense or high level of p53 overexpression. The high level
of p53 accumulation is likely to be associated with mutations
in the p53 gene, and to effect full transformation, the p53
mutants may cooperate with other oncogenes and/or tumour
suppressor genes. Survival of PNET patients appears to be
dependent on sensitivity of their tumours to radiation therapy
(Ito et al., 1992). The poor response of PNET's expressing
high levels of p53 suggests that they are less sensitive to
radiotherapy than tumours showing low levels of p53 immuno-
reactivity. This runs counter to the previous proposals that p53
abnormalities may make tumour cells more responsive to
DNA damaging agents (Lane, 1992; Vogelstein & Kinzler,
1992). However, more recently it has been demonstrated that
wild type p53 is essential for the apoptic response of
thymocytes to ionising radiation (Lowe et al., 1993; Clarke et
al., 1993), and it has been proposed that abrogation of the p53
pathway may be involved in the poor response of many
human tumours to treatment by radiation and chemothera-
peutic drugs (Lane, 1993). It remains to be established whether
such p53 mediated responses are relevant to PNET's. We are
currently engaged in DNA sequencing studies to further
elucidate the relationship between the intensity of p53 overex-
pression, p53 gene mutation, and survival in PNET patients.
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